Orna Therapeutics - Crunchbase Company Profile & Funding

Q: Who invested in Orna Therapeutics?

Orna Therapeutics has 10 investors including MPM Capital And BioImpact.

Q: When was the last funding round for Orna Therapeutics?

Orna Therapeutics closed its last funding round on obfuscated from a Series B round.

Q: How much funding has Orna Therapeutics raised to date?

Orna Therapeutics has raised obfuscated.

Overview

Orna Therapeutics

Total Funding

obfuscation

Growth Score

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

Recent Milestones

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

See more interactive data and historical milestones on desktop for the best experience

About Orna Therapeutics

CB Rank

1997

Orna Therapeutics is a biotechnology company that specializes in fully engineered circular RNA therapeutics to treat various diseases.

Acquired by

Eli Lilly

Founded

obfuscation

Private

Series B

Cambridge, Massachusetts, United States

101-250

ornatx.com

Biotechnology

Medical

Pharmaceutical

Therapeutics

Funding Rounds

Series B

OBF

obfuscation

Series A

OBF

obfuscation

Seed

OBF

obfuscation

Key People

Alex Wesselhoeft: Founder & Director, Molecular Biology
Raffaella Squilloni: Founder, Director of Business Development & Former Board Director

Details

Legal Name

Orna Therapeutics, Inc.

Operating Status

Active

Company Type

For Profit

Founders

Alex Wesselhoeft, Daniel Anderson, Raffaella Squilloni

About the Company

Orna Therapeutics is a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA (oRNA) therapeutics with the potential to change the way they treat disease. The company's proprietary platform combines novel technology to create oRNAs that drive protein expression with validated and unique

delivery solutions.

Contact Email

info@ornatx.com

Hub Tags

Exited Unicorn

Diversity Spotlight

Women Founded

Predictions & Insights

Growth Insight

See this Growth Insight

Orna Therapeutics is

Lorem

to be growing

Top Contributing Factors

Recently Raised Funding

Growth Prediction

See this Growth Prediction

Top Contributing Factors

Key Employee Changes

Products & Services

panCAR™ in vivo CAR RNA Therapy

An in vivo therapy using circular RNA and lipid nanoparticles to engineer immune cells for treating autoimmune and oncology diseases.

SiTu Editing in the Marrow (STEM)™ Gene Editing Platform

An in vivo gene editing platform delivering circular RNA via lipid nanoparticles to hematopoietic stem and progenitor cells in bone marrow for genetic disease treatment.

Research & Development

Orna Therapeutics is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated

...

Unlock More with Crunchbase Pro

Full access to financial & funding data on unlimited profiles
Export up to 2k results/month for analysis
Track market signals on competitors, products, and R&D
Preview private company insights and predictions

Financials

Company Funding

Funding Rounds

Investors

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Series B - Orna Therapeutics	3	obfuscated obfuscation	Merck	Series B
obfuscated obfuscation	Series B - Orna Therapeutics	3	obfuscated obfuscation	Merck	Series B
obfuscated obfuscation	Series B - Orna Therapeutics	3	obfuscated obfuscation	Merck	Series B
obfuscated obfuscation	Series B - Orna Therapeutics	3	obfuscated obfuscation	Merck	Series B
obfuscated obfuscation	Series B - Orna Therapeutics	3	obfuscated obfuscation	Merck	Series B

Funding Rounds

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Series B - Orna Therapeutics	3	obfuscated obfuscation	Merck	Series B
obfuscated obfuscation	Series B - Orna Therapeutics	3	obfuscated obfuscation	Merck	Series B
obfuscated obfuscation	Series B - Orna Therapeutics	3	obfuscated obfuscation	Merck	Series B
obfuscated obfuscation	Series B - Orna Therapeutics	3	obfuscated obfuscation	Merck	Series B
obfuscated obfuscation	Series B - Orna Therapeutics	3	obfuscated obfuscation	Merck	Series B

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.

Investor Name	Lead Investor	Funding Round	Partners
MPM Capital	—	Series B - Orna Therapeutics	—
MPM Capital	—	Series B - Orna Therapeutics	—
MPM Capital	—	Series B - Orna Therapeutics	—
MPM Capital	—	Series B - Orna Therapeutics	—
MPM Capital	—	Series B - Orna Therapeutics	—

Investments

Investment Breakdown

Number of Acquisitions

Investment Breakdown

Number of Acquisitions

M&A Details

Orna Therapeutics

was acquired by

Eli Lilly

for

obfuscation

. This deal was done in

Cash

Transaction Name

Orna Therapeutics acquired by Eli Lilly

Acquired by

Eli Lilly

Announced Date

obfuscation

Price

obfuscation

Market Intelligence

People

View Profiles & Contacts

Headcount

101-250

Employee Profiles

Board Members and Advisors

Contacts

124

Employee Profiles

Alex Wesselhoeft Founder & Director, Molecular Biology
Raffaella Squilloni Founder, Director of Business Development & Former Board Director
Daniel Anderson Founder
Frank Neumann Chief Medical Officer